Compare Equinix Inc (EQIX) vs Medpace Holdings Inc (MEDP) Price & Performance

Equinix (EQIX) trades at $1,069.17, up 2.47% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $4.83, beating estimates, and raised its long-term growth outlook amid strong AI infrastructure demand. Revenue grew to $9.22 billion in 2025, with net income margin improving to 15.63%. However, valuation multiples like P/E of 66.44 and EV/EBITDA of 27.58 are elevated, and net cash flow turned negative in 2025 due to heavy investing activities.

The outlook is supported by robust analyst sentiment with a $1,120 consensus price target and 74.51% buy ratings, but risks include high leverage with debt-to-asset ratio rising to 47.13% in 2025 and earnings misses in two of the last three quarters. Investors should weigh growth potential against valuation and execution risks.

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.